

# Fabrizio Stracci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1543047/publications.pdf>

Version: 2024-02-01

158  
papers

8,829  
citations

87723

38  
h-index

46693

89  
g-index

159  
all docs

159  
docs citations

159  
times ranked

14292  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of deprivation and age on staging of breast, colon, rectum and prostate cancer in Umbria region, Italy: a multilevel approach. <i>European Journal of Cancer Prevention</i> , 2022, 31, 85-92.	0.6	1
2	Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort. <i>Cancer</i> , 2022, 128, 364-372.	2.0	8
3	The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation*. <i>British Journal of Dermatology</i> , 2022, 187, 52-63.	1.4	11
4	Impact of Rhabdomyosarcoma Treatment Modalities by Age in a Population-Based Setting. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 309-315.	0.7	7
5	Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28566.	0.8	2
6	Kaposi sarcoma incidence, survival and trends: Data from the information network on rare cancers in Europe (RARECAREnet). <i>Cancer Epidemiology</i> , 2021, 70, 101877.	0.8	3
7	Complexity index in sarcoma and genomic grade index gene signatures in rhabdomyosarcoma of pediatric and adult ages. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28987.	0.8	7
8	Evaluation of Lumipulse® G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening. <i>International Journal of Infectious Diseases</i> , 2021, 105, 391-396.	1.5	40
9	Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1884-1894.	1.1	6
10	Role of Nucleocapsid Protein Antigen Detection for Safe End of Isolation of SARS-CoV-2 Infected Patients with Long Persistence of Viral RNA in Respiratory Samples. <i>Journal of Clinical Medicine</i> , 2021, 10, 4037.	1.0	6
11	Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. <i>Cancer Medicine</i> , 2021, 10, 6855-6867.	1.3	12
12	Reasons for low cervical cancer survival in new accession European Union countries: a EURO CARE-5 study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 591-602.	0.8	7
13	Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. <i>JCO Oncology Practice</i> , 2020, 16, e211-e220.	1.4	11
14	Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data. <i>European Journal of Health Economics</i> , 2020, 21, 1003-1013.	1.4	12
15	Mathematical Modeling and Robustness Analysis to Unravel COVID-19 Transmission Dynamics: The Italy Case. <i>Biology</i> , 2020, 9, 394.	1.3	4
16	A system for classifying cancers diagnosed in adolescents and young adults. <i>Cancer</i> , 2020, 126, 4634-4659.	2.0	25
17	Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study. <i>Genes</i> , 2020, 11, 925.	1.0	8
18	Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. <i>Thoracic Cancer</i> , 2020, 11, 1661-1669.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. <i>Frontiers in Immunology</i> , 2020, 11, 839.	2.2	28
20	Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1151-1159.	0.5	9
21	Measles immunity in healthcare workers of an Italian hospital. <i>Journal of Infection and Public Health</i> , 2020, 13, 1123-1125.	1.9	7
22	Cancer Mortality and Deprivation: Comparison Among the Performances of the European Deprivation Index, the Italian Deprivation Index and Local Socio-Health Deprivation Indices. <i>Social Indicators Research</i> , 2020, 151, 599-620.	1.4	2
23	Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). <i>ESMO Open</i> , 2020, 5, e000666.	2.0	28
24	Adolescent and Young Adult Cancer Survivors: Design and Characteristics of the First Nationwide Population-Based Cohort in Italy. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 586-593.	0.7	4
25	Networking in rare cancers: What was done, what's next. <i>European Journal of Surgical Oncology</i> , 2019, 45, 16-18.	0.5	23
26	Is the cancer survival improvement in European and American adolescent and young adults still lagging behind that in children?. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27407.	0.8	32
27	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019, 20, e652-e660.	1.1	6
28	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. <i>Stroke</i> , 2019, 50, 2555-2557.	1.0	20
29	Changes in life expectancy for cancer patients over time since diagnosis. <i>Journal of Advanced Research</i> , 2019, 20, 153-159.	4.4	16
30	<p>&lt;p>Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications&lt;/p>&lt;/p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8829-8833.	0.9	15
31	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. <i>Frontiers in Oncology</i> , 2019, 9, 837.	1.3	13
32	Incidence of rare cancers in the city of São Paulo, Brazil. <i>Tumori</i> , 2019, 105, 22-30.	0.6	6
33	Prognosis and cure of long-term cancer survivors: A population-based estimation. <i>Cancer Medicine</i> , 2019, 8, 4497-4507.	1.3	24
34	The European study on centralisation of childhood cancer treatment. <i>European Journal of Cancer</i> , 2019, 115, 120-127.	1.3	12
35	Intensive tobacco cultivations, a possible public health risk?. <i>Environmental Science and Pollution Research</i> , 2019, 26, 12616-12621.	2.7	3
36	Excess risk of dying of other causes of cured cancer patients. <i>Tumori</i> , 2019, 105, 199-204.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. <i>Cancer Epidemiology</i> , 2019, 59, 258-264.	0.8	18
38	Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. <i>European Journal of Cancer</i> , 2019, 110, 120-126.	1.3	61
39	Geospatial analysis of the influence of family doctor on colorectal cancer screening adherence. <i>PLoS ONE</i> , 2019, 14, e0222396.	1.1	8
40	Integrating population data in a computerized Decision Support System for Head and Neck Cancer. , 2019, , .		0
41	Chordoma: update on disease, epidemiology, biology and medical therapies. <i>Current Opinion in Oncology</i> , 2019, 31, 114-120.	1.1	70
42	Cancer of the anal region. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 115-127.	2.0	40
43	Treatment challenges in and outside a network setting: Soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 31-39.	0.5	27
44	Epidemiology of rare cancers and inequalities in oncologic outcomes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 3-11.	0.5	47
45	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 46-51.	0.5	3
46	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 67-74.	0.5	22
47	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 75-80.	0.5	15
48	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. <i>European Journal of Surgical Oncology</i> , 2019, 45, 60-66.	0.5	4
49	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2019, 45, 40-45.	0.5	27
50	Bayesian estimates of the incidence of rare cancers in Europe. <i>Cancer Epidemiology</i> , 2018, 54, 95-100.	0.8	11
51	Spatial barriers impact upon appropriate delivery of radiotherapy in breast cancer patients. <i>Cancer Medicine</i> , 2018, 7, 370-379.	1.3	9
52	The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. <i>Occupational and Environmental Medicine</i> , 2018, 75, 254-262.	1.3	61
53	Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis?. <i>European Journal of Cancer</i> , 2018, 93, 127-137.	1.3	18
54	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Cancer Burden in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 256-266.	1.0	30
56	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
57	Big Data in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 62.	1.3	38
58	Letter concerning: "Response to: "The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure" by Marinaccio et al". <i>Occupational and Environmental Medicine</i> , 2018, 75, 844.2-845.	1.3	0
59	Survival of adults with cancers of bone or soft tissue in Europe"Report from the EURO CARE-5 study. <i>Cancer Epidemiology</i> , 2018, 56, 146-153.	0.8	30
60	Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. <i>BMJ Open</i> , 2018, 8, e020627.	0.8	11
61	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	1.1	15
62	Validating malignant melanoma ICD-9-CM codes in Umbria, ASL Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. <i>BMJ Open</i> , 2018, 8, e020631.	0.8	10
63	Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020. <i>BMC Cancer</i> , 2018, 18, 169.	1.1	42
64	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EURO CARE-5. <i>European Journal of Cancer</i> , 2017, 77, 140-152.	1.3	72
65	Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S24-S31.	0.6	20
66	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S100-S106.	0.6	0
67	Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S70-S76.	0.6	9
68	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. <i>European Journal of Cancer Prevention</i> , 2017, 26, S9-S15.	0.6	7
69	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S114-S120.	0.6	4
70	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S48-S55.	0.6	14
71	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S56-S62.	0.6	3
72	PLAC1 immunization does not induce infertility in mice. <i>Immunotherapy</i> , 2017, 9, 481-486.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Improving treatment results with reference centres for rare cancers: where do we stand?. European Journal of Cancer, 2017, 77, 90-98.	1.3	44
74	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: the EURO-CARE-5 study. European Journal of Cancer, 2017, 84, 335-353.	1.3	29
75	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S85-S91.	0.6	9
76	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S121-S127.	0.6	3
77	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S77-S84.	0.6	13
78	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S92-S99.	0.6	5
79	Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S40-S47.	0.6	7
80	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S16-S23.	0.6	7
81	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S32-S39.	0.6	4
82	Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S63-S69.	0.6	15
83	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S107-S113.	0.6	10
84	Burden and centralised treatment in Europe of rare tumours: results of the RARECARE network population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	5.1	285
85	Geographical variability in survival of European children with central nervous system tumours. European Journal of Cancer, 2017, 82, 137-148.	1.3	33
86	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. European Journal of Cancer Prevention, 2017, 26, S3-S8.	0.6	3
87	Red reflex examination in neonates: evaluation of 3 years of screening. International Ophthalmology, 2017, 37, 1199-1204.	0.6	16
88	Accreditation for centers of sarcoma surgery. Updates in Surgery, 2017, 69, 1-7.	0.9	14
89	Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatric Blood and Cancer, 2017, 64, e26348.	0.8	32
90	Personalise Medicine, Do Not Medicalise Persons. European Urology, 2017, 71, 128-129.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Benefits and Risks of Machine Learning Decision Support Systems. JAMA - Journal of the American Medical Association, 2017, 318, 2354.	3.8	10
92	Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study. Tumori, 2017, 103, 22-32.	0.6	26
93	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. Tumori, 2017, 103, 292-298.	0.6	1
94	Trends in Lung Cancer and Smoking Behavior in Italy: An Alarm Bell for Women. Tumori, 2017, 103, 543-550.	0.6	12
95	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of <i>IGFBP6</i> . Oncotarget, 2017, 8, 60826-60840.	0.8	21
96	Socioeconomic deprivation worsens the outcomes of Italian women with hormone receptor-positive breast cancer and decreases the possibility of receiving standard care. Oncotarget, 2017, 8, 68402-68414.	0.8	8
97	Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol: Table 1. BMJ Open, 2016, 6, e010547.	0.8	17
98	Human papillomavirus and gastrointestinal cancer: A review. World Journal of Gastroenterology, 2016, 22, 7415.	1.4	46
99	Seasonal Variation in Skin Cancer Diagnosis. Frontiers in Public Health, 2016, 4, 78.	1.3	7
100	Survival of European adolescents and young adults diagnosed with cancer in 2000-2007: population-based data from EUROCORE-5. Lancet Oncology, The, 2016, 17, 896-906.	5.1	205
101	Diagnosis and management of typical and atypical lung carcinoids. Critical Reviews in Oncology/Hematology, 2016, 100, 167-176.	2.0	35
102	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. European Journal of Cancer, 2016, 67, 91-98.	1.3	17
103	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. Tumori, 2016, 102, 18-30.	0.6	8
104	209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. Journal of Thoracic Oncology, 2016, 11, S147.	0.5	0
105	Thymoma and thymic carcinomas. Critical Reviews in Oncology/Hematology, 2016, 99, 332-350.	2.0	220
106	Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCORE-5 study. European Journal of Cancer, 2015, 51, 2206-2216.	1.3	82
107	Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCORE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	1.3	66
108	Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues. Occupational and Environmental Medicine, 2015, 72, 648-655.	1.3	52

#	ARTICLE	IF	CITATIONS
109	Specialized teams or specialist networks for rare cancers?. European Journal of Surgical Oncology, 2015, 41, 1115-1117.	0.5	10
110	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Annals of Oncology, 2015, 26, 300-306.	0.6	77
111	Changes in cervical cancer incidence following the introduction of organized screening in Italy. Preventive Medicine, 2015, 75, 56-63.	1.6	35
112	Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry. BMC Cancer, 2015, 15, 286.	1.1	45
113	Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCORE-5. European Journal of Cancer, 2015, 51, 2217-2230.	1.3	75
114	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCORE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	1.3	344
115	Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCORE-5. European Journal of Cancer, 2015, 51, 2144-2157.	1.3	138
116	The EUROCORE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
117	Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCORE-5 study. European Journal of Cancer, 2015, 51, 2242-2253.	1.3	73
118	Psychiatric needs of male prison inmates in Italy. International Journal of Law and Psychiatry, 2015, 41, 82-88.	0.5	18
119	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCORE-5. European Journal of Cancer, 2015, 51, 2169-2178.	1.3	115
120	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Annals of Oncology, 2015, 26, 838-847.	0.6	21
121	Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses. Anticancer Research, 2015, 35, 6341-51.	0.5	2
122	Epidemiologic surveillance of mesothelioma in Umbria. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2015, 27, 526-32.	0.5	1
123	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiology, 2014, 38, 670-678.	0.8	174
124	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii113-iii123.	0.6	212
125	Cancer survival in Europe 1999-2007 by country and age: results of EUROCORE-5-a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
126	Childhood cancer survival in Europe 1999-2007: results of EUROCORE-5-a population-based study. Lancet Oncology, The, 2014, 15, 35-47.	5.1	799

#	ARTICLE	IF	CITATIONS
127	Colorectal Cancer Screening: Tests, Strategies, and Perspectives. <i>Frontiers in Public Health</i> , 2014, 2, 210.	1.3	83
128	Cancer rehabilitation services: an Italian population-based cohort study. <i>Tumori</i> , 2014, 100, 346-51.	0.6	0
129	Corrigendum to "Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe" [Eur. J. Cancer 48 (2) (2012) 159-169]. <i>European Journal of Cancer</i> , 2013, 49, 766.	1.3	2
130	Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project. <i>Cancer Epidemiology</i> , 2013, 37, 850-856.	0.8	21
131	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. <i>European Journal of Cancer</i> , 2013, 49, 2565-2578.	1.3	91
132	Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. <i>European Journal of Cancer</i> , 2013, 49, 684-695.	1.3	519
133	Cancer prevalence estimates in Europe at the beginning of 2000. <i>Annals of Oncology</i> , 2013, 24, 1660-1666.	0.6	36
134	Variations in Cancer Survival and Patterns of Care Across Europe: Roles of Wealth and Health-Care Organization. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 79-87.	0.9	38
135	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 124-130.	0.9	28
136	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. <i>Haematologica</i> , 2013, 98, 744-752.	1.7	35
137	Estimates of cancer burden in Umbria. <i>Tumori</i> , 2013, 99, 342-350.	0.6	4
138	Incidence of multiple primary cancers following respiratory tract cancer in Umbria, Italy. <i>Igiene E Sanità Pubblica</i> , 2013, 69, 629-38.	0.4	0
139	Information Technology as Tools for Cancer Registry and Regional Cancer Network Integration. <i>IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans</i> , 2012, 42, 1410-1424.	3.4	24
140	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 159-169.	1.3	37
141	Rare cancers of the head and neck area in Europe. <i>European Journal of Cancer</i> , 2012, 48, 783-796.	1.3	55
142	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1167-1175.	1.3	71
143	Incidence and survival of rare urogenital cancers in Europe. <i>European Journal of Cancer</i> , 2012, 48, 456-464.	1.3	132
144	Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. <i>European Journal of Cancer</i> , 2012, 48, 1417-1424.	1.3	42

#	ARTICLE	IF	CITATIONS
145	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1532-1542.	1.3	248
146	Embryonal cancers in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1425-1433.	1.3	39
147	Carcinoma of endocrine organs: Results of the RARECARE project. <i>European Journal of Cancer</i> , 2012, 48, 1923-1931.	1.3	43
148	Invasive extramammary Paget's disease and the risk for secondary tumours in Europe. <i>European Journal of Surgical Oncology</i> , 2012, 38, 214-221.	0.5	63
149	Incidence, survival and prevalence of myeloid malignancies in Europe. <i>European Journal of Cancer</i> , 2012, 48, 3257-3266.	1.3	158
150	The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. <i>Tumori</i> , 2012, 98, 550-8.	0.6	6
151	Rare cancers are not so rare: The rare cancer burden in Europe. <i>European Journal of Cancer</i> , 2011, 47, 2493-2511.	1.3	573
152	Quality of life in clinical trials for children. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 41-47.	0.8	8
153	Cancer registry and information technology: A new management system for integrating cancer registry and oncology departments. , 2010, , .		1
154	The Burden of Rare Cancers in Europe. <i>Advances in Experimental Medicine and Biology</i> , 2010, 686, 285-303.	0.8	52
155	Availability of medicines for rare diseases in EU Countries. <i>Pharmaceuticals Policy and Law</i> , 2009, 11, 101-109.	0.1	7
156	Cancer Screenings, Diagnostic Technology Evolution, and Cancer Control. <i>Methods in Molecular Biology</i> , 2009, 471, 107-136.	0.4	7
157	Cancer mortality trends in the Umbria region of Italy 1978-2004: a joinpoint regression analysis. <i>BMC Cancer</i> , 2007, 7, 10.	1.1	23
158	Covid-19 outbreak in Lombardy: impact on reducing solid cancer diagnoses in 2020. <i>International Journal of Cancer</i> , 0, , .	2.3	5